Prognosis Prediction Using Magnetic Resonance Spectroscopy and Oligoclonal Bands in Central Nervous System Methotrexate-associated Lymphoproliferative Disorder

Intern Med. 2022 Dec 15;61(24):3733-3738. doi: 10.2169/internalmedicine.9296-21. Epub 2022 May 21.

Abstract

Central nervous system methotrexate-associated lymphoproliferative disorder (CNS-MTX-LPD) is rare, but its spontaneous regression has been observed in some patients after withdrawal of agents. We herein report three cases of primary CNS-MTX-LPD that received oral MTX for rheumatoid arthritis. Epstein-Barr virus and oligoclonal bands (OCBs) were positive, while proton magnetic resonance spectroscopy (1H-MRS) showed an elevated lipid peak and slightly elevated choline/N-acetylaspartate ratio in common. After MTX withdrawal, brain lesions showed spontaneous regression in all cases. Our patient's 1H-MRS findings and OCBs may reflect a non-monoclonal lymphoproliferative histology as benign-type lesions in CNS-MTX-LPD.

Keywords: EBV; MRS; methotrexate-associated lymphoproliferative disorder; oligoclonal bands.

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • Central Nervous System / pathology
  • Epstein-Barr Virus Infections* / pathology
  • Herpesvirus 4, Human
  • Humans
  • Lymphoproliferative Disorders* / chemically induced
  • Lymphoproliferative Disorders* / diagnostic imaging
  • Lymphoproliferative Disorders* / drug therapy
  • Magnetic Resonance Spectroscopy
  • Methotrexate / adverse effects
  • Oligoclonal Bands / therapeutic use
  • Prognosis

Substances

  • Methotrexate
  • Oligoclonal Bands
  • Antirheumatic Agents